Business
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
CULVER CITY, Calif., February 20, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region.
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/6a888523450db3dc6402b45c71271f7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cqZ8F4cIKuNd8ZppDSyxAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6a888523450db3dc6402b45c71271f7d","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA)","length":128,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi Arabia to support physicians and healthcare systems throughout the MENA region","length":152,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Registration Certificate of Pharmaceutical Product with pricing has been issued to ImmunityBio from the Saudi FDA","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ANKTIVA will be available for distribution within the next 60 days","length":66,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Initiated discussion with Saudi FDA and UAE regulatory authorities to expand ANKTIVA indications beyond Lung and Bladder cancers","length":128,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":591,"olType":false},{"type":"text","content":"CULVER CITY, Calif., February 20, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region.","length":411,"tagName":"p"},{"type":"text","content":"Under the agreement, Biopharma and Cigalah Healthcare will support the commercialization and distribution of ANKTIVA in two indications: In combination with Bacillus Calmette-Guérin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ, with or without papillary disease; and...